ArticleStem cells translational medicine2017
Report of the International Stem Cell Banking Initiative Workshop Activity: Current Hurdles and Progress in Seed-Stock Banking of Human Pluripotent Stem Cells.
Article in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.Transplant international : official journal of the European Society for Organ Transplantation · 2022Pooled it
- Human iPSC-derived 3D cardiac models for cardiomyopathies: organoids, spheroids, and engineered heart tissues as translational platforms.Stem cells (Dayton, Ohio) · 2026Review
- Perspectives from the 2025 ISCBI/ISCI joint workshop on genetic stability, clonal monitoring, ethical data governance, and global inclusion in stem cell banking.Stem cell research & therapy · 2026Article
- Investigation of the stemness and wound-healing potential of long-term cryopreserved stromal vascular fraction cells.Regenerative therapy · 2025Article
- Transformative Potential of Induced Pluripotent Stem Cells in Congenital Heart Disease Research and Treatment.Children (Basel, Switzerland) · 2025Review
- Standardization of Stem Cell and Regenerative Medicine in China.Advances in experimental medicine and biology · 2025Review
- Current Landscape of iPSC Haplobanks.Stem cell reviews and reports · 2024Review
- Guidelines for managing and using the digital phenotypes of pluripotent stem cell lines.Stem cell reports · 2024Review
- Modeling Retinitis Pigmentosa with Patient-Derived iPSCs.Advances in experimental medicine and biology · 2023Review
- Opportunities and Challenges of Human IPSC Technology in Kidney Disease Research.Biomedicines · 2022Review
- Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies.NPJ Regenerative medicine · 2022Article
- Translating stem cell research into development of cellular drugs-a perspective from manufacture of stem cell products and CMC considerations.Cell proliferation · 2022Review
- Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development.Cell proliferation · 2022Article
- Promising Developments in the Use of Induced Pluripotent Stem Cells in Research of ADHD.Current topics in behavioral neurosciences · 2022Article
- Neuronal cell-based medicines from pluripotent stem cells: Development, production, and preclinical assessment.Stem cells translational medicine · 2021Review
- Generation of patient-specific motor neurons in modeling movement diseases.Neural regeneration research · 2021Article
- Transitioning into GMP-Compliance: Alternative Methods for Producing Retinal Organoids for Transplantation.Translational vision science & technology · 2021Article
- Integrated Collection of Stem Cell Bank Data, a Data Portal for Standardized Stem Cell Information.Stem cell reports · 2021Article
- Human stem cell-based models for studying autism spectrum disorder-related neuronal dysfunction.Molecular autism · 2020Review
- Copy number variant hotspots in Han Taiwanese population induced pluripotent stem cell lines - lessons from establishing the Taiwan human disease iPSC Consortium Bank.Journal of biomedical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article summarizes the recent activity of the International Stem Cell Banking Initiative (ISCBI) held at the California Institute for Regenerative Medicine (CIRM) in California (June 26, 2016) and the Korean National Institutes for Health in Korea (October 19-20, 2016). Through the workshops, ISCBI is endeavoring to support a new paradigm for human medicine using pluripotent stem cells (hPSC) for cell therapies. Priority considerations for ISCBI include ensuring the safety and efficacy of a final cell therapy product and quality assured source materials, such as stem cells and primary donor cells. To these ends, ISCBI aims to promote global harmonization on quality and safety control of stem cells for research and the development of starting materials for cell therapies, with regular workshops involving hPSC banking centers, biologists, and regulatory bodies. Here, we provide a brief overview of two such recent activities, with summaries of key issues raised. Stem Cells Translational Medicine 2017;6:1956-1962.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.